Welcome to our dedicated page for Alto Neuroscienc news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscienc stock.
Alto Neuroscience Inc (ANRO) is a new paradigm in mental health treatment, developing personalized therapies for depression and schizophrenia through neurobiological biomarkers. This page serves as the definitive source for verified updates about this clinical-stage biopharmaceutical innovator.
Investors and researchers will find essential information about ANRO's drug development pipeline, including clinical trial progress for assets like ALTO-100 and ALTO-300. Our curated news collection covers regulatory milestones, research partnerships, and scientific advancements in precision psychiatry.
Key updates include biomarker validation studies, FDA designations, and trial result analyses. All content undergoes strict verification to ensure alignment with financial disclosure standards and medical reporting best practices.
Bookmark this page for streamlined access to ANRO's latest developments in brain-based treatment innovation. Check regularly for authoritative updates on psychiatric drug development and personalized medicine breakthroughs.
Alto Neuroscience (NYSE: ANRO) presented significant findings at the Society of Biological Psychiatry Annual Meeting 2025, highlighting advancements in their precision psychiatry pipeline. The company successfully identified and validated an EEG-based biomarker for predicting placebo response in major depressive disorder (MDD) patients, potentially improving clinical trial efficiency.
Key developments include:
- Validation of EEG biomarker's ability to predict placebo response in MDD trials, with significant correlations in ALTO-100 Phase 2b and EMBARC sertraline trials
- New mechanistic insights linking ALTO-300's action to EEG biomarker patterns through 5-HT2C antagonism and dopamine regulation
- Positive results from ALTO-101's preclinical rescue study, demonstrating its potential for treating cognitive impairment in schizophrenia
- ALTO-203 showed promise in reversing anhedonia-like behavior in preclinical studies
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in the upcoming JonesResearch Virtual CNS Day.
The company's management team will deliver a presentation on Tuesday, April 29, 2025, at 12:30 pm ET and engage in one-on-one investor meetings. Interested parties can access the presentation through a live webcast available on the Events and Presentations page in the Investors section of Alto's website, with a replay option available after the event.
Alto Neuroscience (NYSE: ANRO) reported its full-year 2024 financial results and pipeline updates. The company ended 2024 with a strong cash position of $169 million, expected to fund operations into 2028. Key financial metrics include R&D expenses of $47.0 million, G&A expenses of $21.6 million, and a net loss of $61.4 million.
Pipeline highlights include:
- ALTO-300: Favorable interim analysis in Phase 2b MDD trial with topline results expected mid-2026
- ALTO-203: Completed enrollment in Phase 2 MDD trial with data expected Q2 2025
- ALTO-101: New transdermal formulation showing improved drug exposure; Phase 2 schizophrenia trial data expected H2 2025
- ALTO-100: Ongoing Phase 2b trial in bipolar depression with data expected H2 2026
The company strengthened its patent portfolio with new grants covering ALTO-300 and ALTO-100 in biomarker-defined populations, extending protection until 2044 and 2043 respectively.
High-Trend International Group (NASDAQ: HTCO) has announced significant leadership changes, appointing Christopher Nixon Cox as Chairman and Bo Cui as Chief Legal Officer. Cox, who replaces Jinyu Chang (who remains a director), brings extensive experience in global markets and sustainability. He currently serves as CEO of Lightswitch Capital, Argali Carbon , and BioSource Feed , with previous roles including Vice Chairman of Brightsphere, Inc.
Cox's appointment aims to drive HTCO's strategic growth in innovation-driven sectors, particularly focusing on maritime low-carbon initiatives and ocean-based decarbonization. Bo Cui joins with over 20 years of experience in cross-border finance and M&A, having previously led $10 billion in strategic deals at HNA Group.
CEO Shixuan He emphasized that Cox's expertise in capital markets and green technologies aligns with the company's vision, while Cui's background in law and emerging technologies will strengthen their legal strategy and risk management during global expansion.
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in three upcoming investor conferences in March 2025:
1. TD Cowen 45th Annual Health Care Conference (March 3-5, 2025)
- Presentation: Tuesday, March 4, 2025, at 9:50 am ET
- Location: Marriott Copley Place, Boston, MA
2. Leerink's Global Healthcare Conference 2025 (March 10-12, 2025)
- Presentation: Wednesday, March 12, 2025, at 8:00 am ET
- Location: W South Beach, Miami, FL
3. Stifel 2025 Virtual CNS Forum (March 18-19, 2025)
- Presentation: Tuesday, March 18, 2025, at 1:00 pm ET
All available presentations will be accessible via live webcast on the Events and Presentations page in the Investors section of Alto's website, with replays available following each presentation.
Alto Neuroscience (NYSE: ANRO) has been granted U.S. Patent Number 12,226,375 for its precision medicine approach in treating Major Depressive Disorder (MDD). The patent covers the use of ALTO-300 (agomelatine) as an adjunctive therapy for patients who have shown inadequate response to antidepressants, specifically using electroencephalogram (EEG) measures for patient selection.
ALTO-300 is an oral, small molecule designed to function as a melatonin agonist and 5-HT2C antagonist. The patent protection extends until 2044, not accounting for potential extensions. The treatment is being developed as an adjunctive therapy for biomarker-characterized MDD patients in the United States who haven't responded adequately to standard antidepressant treatments.
Alto Neuroscience (NYSE: ANRO) announced favorable interim analysis results for its Phase 2b trial of ALTO-300, an adjunctive treatment for major depressive disorder (MDD). The trial will continue with an increased target of approximately 200 biomarker-positive patients in the final analysis sample, up from the current 87 patients.
The double-blind, placebo-controlled study is enrolling patients characterized by an EEG biomarker signature. ALTO-300, an oral small molecule acting as a melatonin agonist and 5-HT2C antagonist, is being tested as an addition to background antidepressant therapy in patients with inadequate response. The primary outcome measure is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score.
The company reported an estimated preliminary 2024 year-end cash balance of $168 million, expected to support planned operations into 2028. Topline results are anticipated in mid-2026.
Alto Neuroscience (NYSE: ANRO) presented multiple studies at the 63rd ACNP annual meeting, showcasing progress in their precision psychiatry platform. The company highlighted new mechanistic findings supporting the ALTO-300 biomarker, which measures reduced neural signal stability and is linked to 5-HT2C receptor activity.
Key presentations included data on neural mechanisms of the ALTO-300 biomarker, validation of reward processing assessments for ALTO-203 trials, and findings on cognitive impairment in depression. The company announced plans for an interim analysis of the ongoing ALTO-300 Phase 2b trial in Q1 2025, with complete topline data expected in H1 2025.
Alto Neuroscience reported Q3 2024 financial results with a cash position of $182 million, expected to fund operations into 2027. The company announced topline data expectations from two MDD trials in H1 2025 for ALTO-300 and ALTO-203. While the ALTO-100 Phase 2b study in MDD did not meet its primary endpoint, it showed promising results in adjunctive treatment. R&D expenses increased to $13.1 million from $8.0 million YoY, while G&A expenses rose to $5.8 million from $1.8 million. Net loss widened to $16.8 million compared to $9.1 million in Q3 2023.